Table 5. GLM results evaluating for the association between antibiotic susceptibilities of the strains with TOI or IAM.
| Generalized linear model (GLM) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Type of infection (TOI) | Infection acquired model (IAM) | |||||||
| Antibiotics | Estimate | Std. Error | z value | Pr (>|z|) | Estimate | Std. Error | z value | Pr (>|z|) |
| CPD10 | 19.43 | 516.05 | 0.04 | 0.97 | −16.63 | 836.09 | −0.02 | 0.98 |
| CRO30 | 35.64 | 12,692.62 | 0 | 1 | −33.79 | 6,711.99 | −0.01 | 1 |
| ETP10 | RD | RD | RD | RD | RD | RD | RD | RD |
| CIP5 | 0.49 | 0.48 | 1.02 | 0.31 | −1.07 | 0.68 | −1.57 | 0.12 |
| AMC | −0.13 | 0.6 | −0.21 | 0.83 | −2.18 | 1 | −2.18 | 0.03* |
| TZP | 0.81 | 1.01 | 0.8 | 0.42 | −0.04 | 1.38 | −0.03 | 0.97 |
| FOX | 0.06 | 0.54 | 0.12 | 0.91 | −0.32 | 0.68 | −0.48 | 0.63 |
| CAZ | −1.42 | 0.91 | −1.57 | 0.12 | −1.33 | 1.7 | −0.79 | 0.43 |
| CTX | RD | RD | RD | RD | RD | RD | RD | RD |
| FEP | RD | RD | RD | RD | RD | RD | RD | RD |
| IPM | 1.86 | 0.85 | 2.18 | 0.03* | 0.85 | 1.24 | 0.69 | 0.49 |
| MEM | −35.18 | 8,010.3 | 0 | 1 | 30.83 | 1,024 | 0.03 | 0.98 |
| ATM | RD | RD | RD | RD | RD | RD | RD | RD |
| SXT | RD | RD | RD | RD | RD | RD | RD | RD |
| FLO | 0.7 | 0.72 | 0.98 | 0.33 | 0.7 | 0.99 | 0.7 | 0.48 |
Notes:
CPD10, Cefpodoxime; CRO30, Ceftriaxone; ETP10, Ertapenem; CIP5, Ciprofloxacin; AMC, Amoxicillin-clavulanic acid; TZP, Piperacillin-tazobactam; FOX, Cefoxitin; CAZ, Ceftazidime; CTX, Cefotaxime; FEP, Cefepime; IPM, Imipenem; MEM, Meropenem; ATM, Aztreonam; SXT, Trimethoprim-sulfamethoxazole; FLO, Flomoxef.
*
Significance at p ≤ 0.05.